Medvi and Henry Meds compete for price-conscious GLP-1 weight loss patients, with Medvi offering rock-bottom pricing ($149-$349 monthly) and minimal service, while Henry Meds provides value-tier costs ($197-$497 monthly) with complete support. Both offer compounded semaglutide and tirzepatide from 503B facilities, but differ substantially in service quality and patient experience. This evidence-based comparison examines pricing, treatment protocols, support levels, and which platform delivers better value for different patient needs.
Overview: Budget vs Established GLP-1 Weight Loss Platforms
Medvi and Henry Meds occupy different positions in the competitive GLP-1 weight loss market, with Medvi representing the ultra-budget tier and Henry Meds positioned as an established value brand. Both platforms provide access to compounded semaglutide and tirzepatide—the same active pharmaceutical ingredients found in FDA-approved Wegovy and Zepbound—at prices substantially below branded medication costs. The fundamental difference lies in pricing structure, service breadth, and market positioning rather than medication efficacy.
Henry Meds launched in 2022 and rapidly gained market share through competitive pricing, aggressive marketing, and insurance acceptance for consultations. The platform built credibility through partnerships with 503B-registered compounding facilities and transparent communication about compounding regulations. According to
FDA guidance on compounded medications, 503B facilities can legally produce compounded versions of medications experiencing shortages or when medically necessary, providing the regulatory foundation for both platforms' offerings.
Medvi entered the market more recently, targeting the most price-sensitive segment with monthly costs below virtually all competitors. The platform stripped services to essentials: basic provider consultations, medication delivery, and minimal ongoing support. This bare-bones approach enables pricing that undercuts established players by 30-50%, appealing to self-directed patients prioritizing medication access over complete weight loss programming. However, the newer platform lacks the operational track record and customer base that Henry Meds has accumulated.
Clinical evidence for GLP-1 medications comes from the same source regardless of platform. The
STEP trial program published in NEJM demonstrated semaglutide 2.4mg weekly produces average 14.9% total body weight loss over 68 weeks, while
SURMOUNT trials showed tirzepatide achieving 15-21% weight loss depending on dose. Both platforms leverage this evidence base and provide the same medications, making the comparison focus on cost, service quality, and long-term sustainability rather than efficacy differences.
Cost Analysis: Extreme Budget vs Value-Tier Pricing
Medvi employs the most aggressive pricing in the GLP-1 weight loss space. Compounded semaglutide starts at $149 monthly for introductory doses (0.25mg-0.5mg weekly), increasing to $199 monthly for maintenance doses (1mg-1.7mg weekly) and $249 monthly for maximum therapeutic doses (2.4mg weekly). Compounded tirzepatide begins at $249 monthly for starter doses (2.5mg-5mg weekly) and scales to $349 monthly for higher therapeutic doses (10mg-15mg weekly). These prices include provider consultations, prescription management, and medication shipping.
Henry Meds positions slightly higher in the value tier while remaining well below premium platforms. Compounded semaglutide costs $197 monthly for starting doses, $247 monthly for mid-range doses (1mg weekly), and $297 monthly for maximum doses (2.4mg weekly). Compounded tirzepatide runs $297 monthly for introductory doses (2.5mg-5mg weekly) and $397-$497 monthly for therapeutic doses (7.5mg-15mg weekly). The platform accepts some insurance for initial consultations and offers HSA/FSA payment options, providing additional value for patients with health spending accounts.
Over a typical 12-month weight loss journey, cost differences become substantial. A patient progressing from starter to maintenance semaglutide doses would invest approximately $2,388 at Medvi (averaging $199/month × 12) versus $2,964 at Henry Meds (averaging $247/month × 12), a savings of $576 annually. For tirzepatide users reaching therapeutic doses, annual costs run approximately $3,588 at Medvi versus $4,764 at Henry Meds, saving $1,176 with the budget platform.
However, pricing transparency and consistency differ between platforms. Henry Meds clearly communicates all costs upfront with itemized pricing on their website. Customer reviews on
Trustpilot averaging 4.6/5 stars consistently praise transparent billing without surprise charges. Medvi, being newer with fewer reviews, has less established track record for billing practices. Some early user reports note occasional discrepancies between quoted and charged prices, though the platform maintains overall lower costs than competitors.
According to
IRS Publication 502 on medical deductions, prescription medications for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions qualify for HSA/FSA reimbursement. Both platforms provide itemized receipts suitable for reimbursement claims. Henry Meds additionally processes some insurance for consultation fees, while Medvi operates entirely cash-pay. The baseline price advantage at Medvi may offset Henry Meds' insurance acceptance for many patients, though those with generous health spending accounts might find the additional services at Henry Meds worth the premium.
Medication and Dosing: Identical Drugs, Different Support Levels
Both platforms provide compounded semaglutide and tirzepatide sourced from FDA-registered 503B outsourcing facilities that meet current good manufacturing practice (cGMP) standards. The medications contain the same active pharmaceutical ingredients as brand-name Wegovy and Zepbound but at substantially lower costs due to compounding economics. According to
FDA regulations on 503B facilities, these compounders undergo regular inspections and must maintain quality standards comparable to traditional pharmaceutical manufacturers.
Dosing protocols follow FDA-approved escalation schedules for both medications. Semaglutide begins at 0.25mg weekly for 4 weeks, increases to 0.5mg weekly for 4 weeks, then 1mg weekly for 4 weeks, continuing to escalate every 4 weeks until reaching the maximum 2.4mg weekly dose. Tirzepatide starts at 2.5mg weekly for 4 weeks, increasing to 5mg, 7.5mg, 10mg, 12.5mg, and maximum 15mg weekly, with 4-week intervals between increases. These schedules minimize gastrointestinal side effects while enabling patients to reach therapeutic doses.
Henry Meds provides complete dosing support including pre-filled syringes with dose-specific markings, detailed injection technique videos, refrigeration guidelines, and side effect management protocols. The platform supplies alcohol swabs, sharps containers, and written instructions with each shipment. Providers conduct regular check-ins to assess tolerance and determine appropriate escalation timing. According to customer reviews, patients value the hand-holding approach, particularly for first-time users intimidated by self-injection.
Medvi offers more basic support: medication vials or pre-filled syringes (depending on selection), standard dosing instructions, and access to provider messaging for questions. The streamlined approach works for self-directed patients comfortable with minimal guidance but may challenge those wanting more structured support. Some users report receiving less detailed injection training and fewer proactive check-ins compared to Henry Meds, though basic safety information and dosing schedules are provided adequately.
Neither platform can prescribe brand-name Wegovy, Ozempic, Mounjaro, or Zepbound directly, as these FDA-approved medications require traditional pharmacy fulfillment and typically cost $1,000-$1,400 monthly without insurance coverage. The compounded versions enable access to the same active drugs at 70-85% cost savings. Research published in
Obesity journal confirms compounded GLP-1 formulations can produce similar weight loss outcomes to branded products when dosed equivalently and sourced from quality facilities, supporting the clinical validity of both platforms' offerings despite lower costs.
Consultation and Support: Established Service vs Minimal Touch
Henry Meds built its reputation on responsive service and accessible providers. Initial consultations occur via video or asynchronous messaging, with patients answering detailed questionnaires about weight history, previous diet attempts, medical conditions, current medications, and weight loss goals. Board-certified physicians or nurse practitioners review submissions within 24 hours, conducting medical screening for GLP-1 contraindications including personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome, and pancreatitis history.
The onboarding process at Henry Meds includes educational materials about realistic weight loss expectations, common side effects (nausea, constipation, diarrhea, decreased appetite), dietary strategies to minimize gastrointestinal symptoms, and when to seek immediate medical attention. Patients receive follow-up outreach at 2-week intervals during the first two months to assess tolerance and address concerns. The platform maintains provider messaging access with typical response times under 24 hours according to
Trustpilot reviews.
Medvi streamlines the intake process with briefer questionnaires focused on basic eligibility screening. The consultation emphasizes contraindication identification and prescription approval rather than extensive education or goal-setting discussion. Patients complete medical history forms, receive provider review within 24-48 hours, and get prescription authorization if medically appropriate. The platform provides standard medication information but less proactive outreach or structured check-ins compared to Henry Meds.
Follow-up care differs substantially in intensity. Henry Meds schedules regular provider touchpoints aligned with dose escalations, encouraging patients to report side effects, discuss progress, and optimize treatment. The platform built systems for tracking adherence, weight changes, and tolerance issues, enabling providers to make informed adjustments. Medvi operates more reactively, with patients initiating contact when questions or problems arise rather than receiving scheduled check-ins. This works adequately for experienced patients or those wanting minimal interaction, but provides less guidance for first-time GLP-1 users.
Customer service responsiveness represents another differentiator. Henry Meds invested in support infrastructure with dedicated teams handling medication questions, billing inquiries, and prescription issues. The platform's
4.6/5 star Trustpilot rating reflects consistent positive experiences with problem resolution and communication. Medvi, being newer and operating on thinner margins, has fewer reviews but shows more variable response times and occasional reports of delayed communication during operational scaling. The service quality trade-off mirrors the cost difference.
Medical Oversight: Standard Screening vs Complete Surveillance
Both platforms implement FDA-recommended safety screening before initiating GLP-1 therapy. According to
FDA safety communications, important contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, and previous severe hypersensitivity to semaglutide or tirzepatide. Henry Meds and Medvi screen for these conditions through medical questionnaires and exclude inappropriate candidates.
Henry Meds recommends (though does not mandate) baseline laboratory testing before starting therapy, including complete metabolic panel, lipase, hemoglobin A1c, and lipid panel. The platform can facilitate lab orders through Quest Diagnostics or LabCorp partnerships for patients wanting pre-treatment assessment. Providers review results and discuss any abnormalities before prescribing. This approach aligns with Endocrine Society guidelines suggesting baseline metabolic assessment for patients starting anti-obesity medications.
Medvi does not routinely require or facilitate laboratory testing, instead relying on patient-reported medical history and symptom monitoring. This reduces costs and barriers but provides less objective safety data. Patients with pre-existing conditions like diabetes, kidney disease, or liver dysfunction may benefit from baseline labs that Medvi does not systematically include. The platform advises patients to contact their primary care doctors for lab work if desired, placing responsibility on patients to coordinate this separately.
Ongoing monitoring protocols differ in structure. Henry Meds actively tracks for concerning symptoms including severe abdominal pain suggesting pancreatitis, rapid heart rate, vision changes, or allergic reactions. The platform provides 24/7 nurse line access for urgent concerns and clear guidance on when to seek emergency care. Regular check-ins create opportunities to identify problems early. Medvi provides similar safety information but monitors more passively, depending on patients to recognize and report concerning symptoms without structured surveillance.
Both platforms educate patients about appropriate weight loss rates—typically 1-2 pounds weekly initially, increasing to 2-3 pounds weekly at therapeutic doses. Excessive weight loss, persistent vomiting, or inability to maintain adequate hydration warrant dose adjustment or temporary discontinuation. The difference lies in how actively each platform monitors these parameters: Henry Meds through regular check-ins and weight tracking systems, Medvi through patient-initiated reporting. For medically complex patients or those with significant comorbidities, the more strong oversight at Henry Meds may justify higher costs.
Weight Loss Results and Patient Satisfaction: Similar Efficacy, Different Experiences
Weight loss outcomes depend primarily on medication, dose achieved, adherence, and lifestyle factors rather than which platform provides the prescription. Both Medvi and Henry Meds patients using semaglutide at therapeutic doses can expect average 12-18% total body weight reduction over 12 months based on clinical trial data. Tirzepatide users typically achieve 15-21% average weight loss at maximum doses, with higher doses producing greater results. Individual outcomes vary based on starting weight, metabolic factors, and behavioral adherence.
Henry Meds patients report high satisfaction with weight loss results in
Trustpilot reviews, frequently mentioning 30-50+ pounds lost over 6-9 months and sustained weight reduction with continued treatment. Positive reviews emphasize feeling supported throughout the process, receiving helpful guidance on managing side effects, and appreciating responsive communication when questions arose. The complete support appears to facilitate better treatment adherence and completion rates.
Medvi users achieving therapeutic doses describe similar weight loss magnitudes—clinical trial-level results when medications work as expected. However, satisfaction comments focus more on cost savings than service experience. Some users appreciate the no-frills approach and report successful weight loss spending less than competitors. Others note wishing they had more support during challenging side effect periods or when unsure about dose escalation timing. The basic service model works well for self-sufficient patients but may contribute to higher discontinuation rates among those needing more guidance.
Treatment adherence and persistence affect long-term outcomes significantly. Research shows
GLP-1 discontinuation rates approach 50-70% by 12 months in real-world settings, often due to side effects, cost concerns, or perceived inadequate results. Platforms providing better support and education may improve persistence. Henry Meds' structured follow-up and side effect management potentially reduce discontinuation versus Medvi's minimal-touch approach, though comparative data is limited.
Long-term value depends on achieving and maintaining therapeutic doses. A patient who tolerates semaglutide well and reaches 2.4mg weekly will likely experience good results at either platform, with Medvi delivering cost savings. A patient experiencing significant side effects or uncertainty about treatment may benefit from Henry Meds' superior support despite higher prices. The weight loss journey involves challenges beyond medication access—nausea management, lifestyle modification, psychological adjustment—where complete platforms provide more value. The optimal choice balances cost consciousness with honest assessment of support needs.
How We Tested Henry Meds vs Medvi
Our Comparison Methodology
This comparison is based on complete analysis of GLP-1 weight loss protocols, pricing structures, service models, and treatment approaches from both platforms, supplemented by peer-reviewed obesity medicine research.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication labels, STEP trial data for semaglutide from New England Journal of Medicine, SURMOUNT trials for tirzepatide, and compounding pharmacy research from Obesity journal.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 efficacy data (14.9-21% weight loss), discontinuation rates from Diabetes, Obesity and Metabolism, treatment guidelines from Endocrine Society, and FDA compounding facility regulations.
Pricing Analysis: All pricing reflects published subscription costs as of January 2026, verified through official platform websites. Costs may vary based on dosage requirements.
Service Verification: Platform capabilities, provider credentials, medication sourcing from FDA-registered 503B facilities, and support services were evaluated through detailed review and Trustpilot customer experiences.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Henry Meds vs Medvi
Choose Medvi if: You are highly budget-conscious, self-directed, and comfortable managing weight loss treatment with minimal medical oversight. The platform delivers the lowest GLP-1 medication prices available ($149-$349 monthly), saving $576-$1,176 annually versus Henry Meds. This works well for confident patients who have researched GLP-1 medications thoroughly, understand dose escalation protocols, can manage common side effects independently, and primarily want medication access without paying for extensive support services. The bare-bones approach maximizes cost savings for those who do not need hand-holding.
Choose Henry Meds if: You want an established platform with proven service quality, complete support, and proactive medical oversight. The moderate premium ($197-$497 monthly, approximately 25-40% higher than Medvi) buys regular provider check-ins, responsive customer service with 24-hour message response times, detailed educational resources, and structured monitoring that may improve treatment adherence and outcomes. This is appropriate for first-time GLP-1 users, patients anticipating side effect challenges, or anyone who values peace of mind from reliable support despite moderately higher costs. The platform's 4.6/5 Trustpilot rating reflects consistently positive patient experiences.
The Bottom Line: Both platforms provide legitimate access to compounded semaglutide and tirzepatide at costs far below brand-name medications ($1,000-$1,400 monthly). The choice depends on whether you prioritize absolute minimum cost or prefer paying somewhat more for substantially better service and support. Medvi operates like a discount warehouse—rock-bottom prices with minimal frills. Henry Meds functions more like a value brand—competitive pricing with solid quality and service. Your decision should align with your support needs, budget constraints, and comfort level managing medical treatments independently versus with structured guidance.
Frequently Asked Questions
Which platform offers lower prices for GLP-1 weight loss medications?
Medvi provides the lowest pricing in the market: $149-$249 monthly for compounded semaglutide and $249-$349 monthly for tirzepatide depending on dose. Henry Meds costs $197-$297 monthly for semaglutide and $297-$497 monthly for tirzepatide. Over 12 months at maintenance doses, Medvi saves approximately $576-$1,176 annually compared to Henry Meds. However, Medvi offers more basic service with minimal check-ins and less educational support, while Henry Meds provides complete onboarding, regular follow-ups, and responsive customer service. If you are budget-focused, self-directed, and comfortable managing treatment independently, Medvi delivers maximum savings. If you value structured support, proactive monitoring, and established service quality, Henry Meds offers better overall value despite higher costs.
Do both platforms provide the same quality medications?
Yes, both platforms source compounded semaglutide and tirzepatide from FDA-registered 503B outsourcing facilities that must meet current good manufacturing practice (cGMP) standards and undergo regular inspections. The medications contain the same active pharmaceutical ingredients as brand-name Wegovy and Zepbound. There is no evidence that one platform's medications are superior in quality or efficacy—clinical outcomes depend on achieving therapeutic doses and individual patient factors rather than compounding source. The difference between platforms lies in service, support, and monitoring rather than medication quality itself.
Does Henry Meds accept insurance while Medvi does not?
Henry Meds accepts some insurance plans for initial consultation fees and can work with FSA/HSA accounts for medication costs, though the GLP-1 medications themselves typically remain cash-pay. Medvi operates entirely on a cash-pay model without insurance processing for any services. Both platforms provide itemized receipts suitable for HSA/FSA reimbursement claims for patients with health spending accounts. According to IRS Publication 502, prescription obesity medications qualify for HSA/FSA use when prescribed for BMI ≥30 or BMI ≥27 with weight-related conditions. Patients with generous HSA/FSA balances may find Henry Meds' insurance coordination helpful, while those paying entirely out-of-pocket benefit more from Medvi's lower baseline prices.
Which platform provides better support for first-time GLP-1 users?
Henry Meds offers substantially more complete support for patients new to GLP-1 medications, including detailed injection training videos, regular check-in calls during the first 8 weeks, proactive side effect monitoring, and responsive provider messaging (typically under 24-hour response time). The platform provides pre-filled syringes with clear dosing markers, complete injection supplies, and extensive educational materials. Medvi offers basic dosing instructions and medication information but fewer proactive touchpoints and less hand-holding. First-time users who feel anxious about self-injection, want regular reassurance, or anticipate needing guidance managing side effects will have better experiences at Henry Meds. Confident, self-directed patients comfortable with minimal supervision can save money at Medvi.
How do the platforms compare for managing side effects?
Henry Meds provides structured side effect management with regular check-ins to assess tolerance, provider messaging for questions about symptoms like nausea or constipation, and clear protocols for dose adjustment if side effects become intolerable. The platform's 24/7 nurse line offers urgent guidance for concerning symptoms. Medvi provides standard side effect information and allows patients to message providers but operates more reactively—patients must initiate contact rather than receiving proactive outreach. For straightforward cases where side effects are mild and manageable, either platform works adequately. For patients experiencing significant gastrointestinal symptoms, difficulty tolerating dose escalations, or uncertainty about concerning versus normal reactions, Henry Meds' active monitoring and support provides more value.
Can I switch between platforms if I want to change later?
Yes, you can switch between platforms since both prescribe the same medications following standard dosing protocols. If you start at Medvi to save money but later want more support, you can transfer to Henry Meds by providing your current dose and treatment history during onboarding. Conversely, if you start at Henry Meds but become comfortable managing treatment independently, you can switch to Medvi for cost savings. The main consideration is ensuring continuity of medication supply during transition—coordinate timing to avoid running out of medication between shipments. Neither platform requires long-term contracts, making switching feasible, though you will go through new patient intake and provider approval at whichever platform you transfer to.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
